Citations 4
Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease
Joseph‐Mathurin, Nelly , Jasielec, Mateusz S., Vlassenko, Andrei G. , Gordon, Brian A. , Hornbeck, Russ C. , Cash, Lisa, Veale, Thomas , Cash, David M. , Buckles, Virginia, Cairns, Nigel J. , Goate, Alison , Karch, Celeste M. , Klunk, William E. , Marcus, Daniel S. , Mayeux, Richard , Noble, James M. , Ringman, John M. , Xiong, Chengjie , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Bateman, Randall J , Joseph-Mathurin, Nelly , Karch, Celeste M , Morris, John C , Cash, David M , Su, Yi , Blazey, Tyler , Friedrichsen, Karl A. , Ances, Beau M. , Brickman, Adam M. , Cruchaga, Carlos , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Saykin, Andrew J. , Thompson, Paul M. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Noble, James M
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | September 27, 2018 | Volume: 10 | Issue: 1 | Pages: 669-677
AbstractIntroduction18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the utility of dynamic PET measures of perfusion using 11C‐Pittsburgh compound B (PiB) to estimate neuronal injury in comparison to FDG PET.MethodsFDG, early frames of PiB images, and relative PiB delivery rate constants (PiB‐R1) were obtained from 110 participants from the Dominantly Inherited Alzheimer Network. Voxelwise, regional cross‐sectional, and longitudinal analyses were done to evaluate the correlation between images and estimate the relationship of the imaging biomarkers with estimated time to disease progression based on family history.ResultsMetabolism and perfusion images were spatially correlated. Regional PiB‐R1 values and FDG, but not early frames of PiB images, significantly decreased in the mutation carriers with estimated year to onset and with increasing dementia severity.DiscussionHypometabolism estimated by PiB‐R1 may provide a measure of brain perfusion without increasing radiation exposure.
[IC‐P‐166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY
Su, Yi , Jasielec, Mateusz S., Vlassenko, Andrei G. , Hornbeck, Russ C. , Cash, Lisa, Raichle, Marcus E. , Buckles, Virginia, Cairns, Nigel J. , Fagan, Anne M. , Klunk, Bill E., Marcus, Daniel S. , Mayeux, Richard , Paumier, Katrina L. , Ringman, John M. , Xiong, Chengjie , Network, Dominantly Inherited Alzheimer, Joseph‐Mathurin, Nelly , Blazey, Tyler , Friedrichsen, Karl A. , Gordon, Brian A. , Ances, Beau M. , Brickman, Adam M. , Cruchaga, Carlos , Goate, Alison , Jack, Clifford R. , Klunk, Bill E., Koeppe, Robert A. , McDade, Eric , Saykin, Andrew J. , Thompson, Paul M. , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer
Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_2 | Pages: No page available
[P2–372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY
Jasielec, Mateusz S., Vlassenko, Andrei G. , Hornbeck, Russ C. , Cash, Lisa, Raichle, Marcus E. , Buckles, Virginia, Cairns, Nigel J. , Fagan, Anne M. , Klunk, Bill E., Marcus, Daniel S., Mayeux, Richard , Paumier, Katrina L. , Ringman, John M. , Network, Dominantly Inherited Alzheimer, Joseph‐Mathurin, Nelly , Su, Yi , Blazey, Tyler , Friedrichsen, Karl A. , Gordon, Brian A. , Ances, Beau M. , Brickman, Adam M. , Cruchaga, Carlos , Goate, Alison , Jack, Clifford R. , Klunk, Bill E., Koeppe, Robert A. , McDade, Eric , Saykin, Andrew J. , Thompson, Paul M. , Xiong, Chengjie , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer
Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_15 | Pages: No page available
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease
Benzinger, Tammie L.S. , Blazey, Tyler , Xiong, Chengjie , Raichle, Marcus E. , Ances, Beau M. , Bateman, Randall J. , Cairns, Nigel J., Fagan, Anne M. , Goate, Alison , Marcus, Daniel S. , Aisen, Paul, Christensen, Jon, Ercole, Lindsay, Hornbeck, Russ C. , Farrar, Angela, Aldea, Patricia, Jasielec, Mateusz S., Owen, Christopher J. , Xie, Xianyun, Mayeux, Richard , Klunk, William E. , Mathis, Chester A. , Ringman, John M. , Thompson, Paul M. , Saykin, Andrew J. , Johnson, Keith A. , Salloway, Stephen , Correia, Stephen , Schofield, Peter R. , Masters, Colin L. , Villemagne, Victor L. , Martins, Ralph N. , Ourselin, Sébastien , Rossor, Martin N. , Fox, Nick C. , Cash, David M. , Weiner, Michael W. , Buckles, Virginia, Moulder, Krista L., Morris, John C. , Jack, Clifford R. , Koeppe, Robert A. , Su, Yi , Xiong, Chengjie , Snyder, Abraham Z. , Brickman, Adam M. , McDade, Eric , Ghetti, Bernardino , Sperling, Reisa Anne , Rowe, Christopher Cleon , Holtzman, David M. , Saykin, Andrew J , Schofield, Peter R , Thompson, Paul M , Bateman, Randall J , Masters, Colin L , Benzinger, Tammie L S , Ances, Beau M , Fox, Nick C , Morris, John C , Cash, David M , Goate, Alison M
Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available
Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.